About MeI am a gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center. I have been on the Ohio State faculty since 2005.
I earned my medical degree from Wayne State University School of Medicine, completed my residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation, and my fellowship at Yale University.
I am actively involved in improving the quality of patient care, safety and satisfaction. I serve as the chair of The James Committee on Patient Satisfaction and am a member of the Patient Experience Counsel, the Perioperative Quality Management Committee and The James Quality and Patient Safety Committee.
I am active nationally as a member of the Marketing and Communication Committee of the Society of Gynecologic Oncologists (SGO) and the Ovarian Cancer, Developmental Therapeutics and Membership Committees of the Gynecologic Oncology Group (GOG). I was appointed to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer. Most recently, I accepted the invitation to be one of three U.S. members of the steering committee for TRINOVA 3, a multinational phase III ovarian cancer trial.
My drive to have no patient with a gynecologic cancer succumb to the disease guides my research that specializes in the development of therapeutics/treatments for gynecologic cancers, concentrating on ovarian and uterine (endometrial). I have designed, coordinated and published on phase I, II and III clinical trials with a special interest in compounds that effect angiogenesis. This led to becoming the institutional principal investigator for the NCCN Ovarian Cancer Outcomes Project. Improving patient treatment options cannot be accomplished without understanding how the treatments are having an effect at the cellular level; therefore, I continue to participate in projects that help define these mechanisms. I work to improve not only the therapies (chemotherapy) but to identify patients that would benefit (or not benefit) from adjuvant therapeutic options in ovarian and uterine cancer (specifically high risk histologies) patients.
My quest to improve patient outcomes has led to working on improving surgical techniques. I have implemented robotic assisted minimally invasive surgical techniques in all aspects of practice, and published the improved outcomes of these techniques. I have collaborated across multiple medical specialties to identify ways to improve the technique and outcomes of how malignant cells are removed at the time of surgery (Ramen spectroscopy). My team has submitted and been awarded grants to study these techniques and my research has been recognized with more than 50 publications.
I have been named as one of the Best/Top Doctors in America by US News and World Report (Castle Connelly) and Best Doctors and I was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017.
- Named to the Castle Connolly list of America’s “Top Doctors” for 2015, 2017
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014, 2016, 2017
- Best Doctor in America 2017
Specialties and conditions I treat
- Gynecologic Oncology
- Gynecologic Cancers
- Ovarian Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Endometrial Cancers
- Cervical Cancer
- Vaginal Cancers
- Vulvar Cancers
Locations where I practice
Stefanie Spielman Comprehensive Breast Center
Education and training
Wayne State University School of Medicine
Obstetrics / Gynecology
Case Western Reserve University
7/1/1999 - 6/30/2002
More about my work
OB/GYN / Gynecological Oncology
Yale University School of Medicine
7/1/2002 - 6/30/2005
American Board of OB/GYN
American Board of OB/GYN (Subspecialty: Gynecologic Oncology)
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/2017, Dr. O'Malley has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.
- Clovis Oncology
- Johnson & Johnson
- Tesaro, Inc.